647 related articles for article (PubMed ID: 11566042)
1. COX-1 and COX-2 inhibitors.
Hawkey CJ
Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):801-20. PubMed ID: 11566042
[TBL] [Abstract][Full Text] [Related]
2. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
[TBL] [Abstract][Full Text] [Related]
4. [COX-2 inhibitor non-steroidal anti-inflammatory drugs, myth or reality?].
Peretz A
Rev Med Brux; 2001 Sep; 22(4):A377-80. PubMed ID: 11680204
[TBL] [Abstract][Full Text] [Related]
5. New NSAIDs and gastroduodenal damage.
Folco GC
Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():28-9. PubMed ID: 9032579
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 inhibitor celecoxib: a possible cause of gastropathy and hypoprothrombinemia.
Linder JD; Mönkemüller KE; Davis JV; Wilcox CM
South Med J; 2000 Sep; 93(9):930-2. PubMed ID: 11005360
[TBL] [Abstract][Full Text] [Related]
7. Are rofecoxib and celecoxib safer NSAIDS?
Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
[TBL] [Abstract][Full Text] [Related]
8. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
[No Abstract] [Full Text] [Related]
9. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
Wynn RL
Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
[No Abstract] [Full Text] [Related]
10. Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Umar A; Boisseau M; Yusup A; Upur H; Bégaud B; Moore N
Fundam Clin Pharmacol; 2004 Oct; 18(5):559-63. PubMed ID: 15482377
[TBL] [Abstract][Full Text] [Related]
11. [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Lamarque D
Bull Cancer; 2004 May; 91 Spec No():S117-24. PubMed ID: 15239340
[TBL] [Abstract][Full Text] [Related]
12. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.
Muscará MN; McKnight W; Asfaha S; Wallace JL
Br J Pharmacol; 2000 Feb; 129(4):681-6. PubMed ID: 10683192
[TBL] [Abstract][Full Text] [Related]
13. [Coxibs: cyclooxygenase-2 inhibitors].
Turnheim K
Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
[TBL] [Abstract][Full Text] [Related]
14. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
15. [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances].
Hinz B; Brune K
Wien Klin Wochenschr; 1999 Feb; 111(3):103-12. PubMed ID: 10093892
[TBL] [Abstract][Full Text] [Related]
16. [Selective cyclooxygenase-2 (COX-2) inhibitors: importance and limitations].
Pairet M; Netter P
Therapie; 1999; 54(4):433-45. PubMed ID: 10667110
[TBL] [Abstract][Full Text] [Related]
17. [Selective cyclooxygenase-2 inhibitors and the digestive tract].
Chaabouni H; Amouri A; Cheikh I; Kchaou M; Ouerghi H; Ben Mami N; Ben Ammar A
Tunis Med; 2002 Aug; 80(8):427-33. PubMed ID: 12703120
[TBL] [Abstract][Full Text] [Related]
18. Adverse Drug Events Involving COX-2 Inhibitors.
Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
[TBL] [Abstract][Full Text] [Related]
19. [COX-2 specific inhibitors: are NSAIDs and the stomach become reconcilied?].
Bannwarth B
Gastroenterol Clin Biol; 2001 Apr; 25(4 Suppl):B79-84. PubMed ID: 11449148
[No Abstract] [Full Text] [Related]
20. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]